Left ventricular dysfunction (LVD) in post-myocardial infarction (MI) patients is
an important predictor of a poor prognosis. LVD may be asymptomatic in the post-MI
patient, but it can also manifest as heart failure (HF) or sudden cardiac death. Early
revascularization and pharmacologic therapy targeting coronary artery disease (CAD)
and LVD reduce post-MI mortality as well as rates of HF and recurrent MI. However,
despite dramatic gains in the treatment of post-MI LVD, there remains considerable
room for improvement. The following is a brief summary of important areas of investigation
addressing this goal.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry.Arch Intern Med. 2005; 165: 1469-1477
- Association between performance measures and clinical outcomes for patients hospitalized with heart failure.JAMA. 2007; 297: 61-70
- Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study.J Am Coll Cardiol. 2003; 41: 997-1003
- Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients: a meta-analysis.Eur J Heart Fail. 2005; 7: 1133-1144
- Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study.J Am Coll Cardiol. 2007; 49: 1733-1739
- Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.Hypertension. 2003; 42: 1137-1143
- Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.Circulation. 2005; 111: 1012-1018
- Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure.Eur J Heart Fail. 2007; 9: 1070-1073
- Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure?.Hypertension. 2007; 49: 974-976
- Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.Hypertension. 2007; 49: 1128-1133
- Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF.Eur J Heart Fail. 2006; 8: 764-766
- Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy.Eur Heart J. 2007; 28: 613-627
- Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy.Circulation. 2005; 112: I-46-I-50
- Heart rate lowering by specific and selective If current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.Drugs. 2004; 64: 1757-1765
- Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.Am Heart J. 2006; 152: 860-866
- Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization.Nature. 2007; 445: 177-182
- A multicenter, randomized, controlled comparison of telephonic disease management vs automated home monitoring in patients recently hospitalized with heart failure: SPAN-CHF II trial.Program and abstracts from the 9th Annual Scientific Meeting of the Heart Failure Society of America, Boca Raton, Fla2005 (September 18-21)
- Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home–Care Management System (TEN-HMS) study.J Am Coll Cardiol. 2005; 45: 1654-1664
- Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: the Weight Monitoring in Heart Failure (WHARF) trial.Am Heart J. 2003; 146: 705-712
- Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION): design and rationale.Am Heart J. 2007; 153: 201-211
- Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial.JAMA. 2007; 297: 1985-1991
- Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis.J Am Coll Cardiol. 2002; 39: 1151-1158
- The heart failure revascularisation trial (HEART): rationale, design and methodology.Eur J Heart Fail. 2003; 5: 295-303
- Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia.N Engl J Med. 1996; 335: 1933-1940
- Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.N Engl J Med. 2002; 346: 877-883
- Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.N Engl J Med. 2004; 350: 2140-2150
- Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT): design and clinical protocol.Ann Noninvasive Electrocardiol. 2005; 10: 34-43
- Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled Stem Cells in Myocardial Infarction (STEMMI) trial.Circulation. 2006; 113: 1983-1992
- Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) trial.Circulation. 2005; 112: I-73-I-80
- Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial.Lancet. 2004; 363: 751-756
- Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.Circulation. 2007; 115: 3165-3172
- Transcoronary transplantation of functionally competent bone marrow cells is associated with decreased natriuretic peptide levels and improved survival in post-infarction heart failure patients [abstract].Eur Heart J. 2007; 28: 297
- Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) study: a multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction.Am Heart J. 2007; 153: 212.e1-212.e7
- Pharmacologic therapies across the continuum of left ventricular function.Am J Cardiol. 2008; 102: 21G-28G
- Device therapies in the post–myocardial infarction patient with left ventricular dysfunction.Am J Cardiol. 2008; 102: 29G-37G
- Percutaneous coronary intervention for myocardial infarction with left ventricular dysfunction.Am J Cardiol. 2008; 102: 38G-41G
- Surgical therapies for post–myocardial infarction patients.Am J Cardiol. 2008; 102: 42G-46G
Article info
Footnotes
Statement of author disclosure: Please see the Author Disclosures section at the end of this article.
Identification
Copyright
© 2008 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
